NCT05974111 COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
| NCT ID | NCT05974111 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ziekenhuis Oost-Limburg |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2023-05-02 |
| Primary Completion | 2025-05-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2023-05-02 with a primary completion date of 2025-05-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study the investigators will assess both procoagulant and anticoagulant pathways using thrombin generation and platelet function tests; as well as neuronal ischemia using cell free DNA in all patients presenting with ischaemic and haemorrhagic stroke (including aneurysmal subarachnoid haemorraghe). Also the cross-talk between inflammation and thrombosis, so-called thrombo-inflammation is further investigated. As such the investigators aim to characterise the patient's coagulation profile before administration of any treatment. By assessing these pathways the investigators strive to detect specific markers to predict vital and functional outcome at 3 months in these patients. Finally the investigators may provide new pathophysiological insights in the course of disease following these events that can possibly improve future therapeutic strategies.
Eligibility Criteria
Inclusion Criteria: Presenting at the hospital with ischaemic stroke, haemorrhagic stroke, aneurysmal subarachnoid haemorrhage or any other type of non-traumatic, intracranial bleeding In patients with minor ischemic stroke (NIHSS \<= 4) only baseline lab sampling will be performed (T0 and T0B). Exclusion Criteria: * Refusal of participation by patient or legal representative * Traumatic intracranial (subdural, subarachnoid, epidural haematoma) bleeding * Patients receiving treatment with interference on coagulation (pro / anti) before first sampling: in this group of patients the coagulation assessment at presentation will be excluded, further lab sampling is performed according to protocol. * Patients categorized as having stroke mimic will be excluded from analysis afterwards
Contact & Investigator
Hendrik Stragier, MD
PRINCIPAL INVESTIGATOR
Ziekenhuis Oost-Limburg
Frequently Asked Questions
Who can join the NCT05974111 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05974111 currently recruiting?
Yes, NCT05974111 is actively recruiting participants. Contact the research team at hendrik.stragier@zol.be for enrollment information.
Where is the NCT05974111 trial being conducted?
This trial is being conducted at Genk, Belgium.
Who is sponsoring the NCT05974111 clinical trial?
NCT05974111 is sponsored by Ziekenhuis Oost-Limburg. The principal investigator is Hendrik Stragier, MD at Ziekenhuis Oost-Limburg. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.